PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: rPeptide, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Alpha Synuclein-rPeptide Introduces New Proteins - Alpha Synuclein, 1-60 Alpha Synuclein, 1-95 Alpha Synuclein, 61-140 Alpha Synuclein, 96-140
Alpha Synuclein-rPeptide Introduces New Proteins

 

NewswireToday - /newswire/ - Bogart, GA, United States, 2008/05/15 - Alpha Synuclein, 1-60 Alpha Synuclein, 1-95 Alpha Synuclein, 61-140 Alpha Synuclein, 96-140.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Alpha Synuclein, 1-60
MW: 6,149 Da
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-60), which contains the N-terminal amphipathic domain. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.
References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha Synuclein, 1-95
MW: 9,391 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-95), which contains the N-terminal amphipathic domain and the NAC region. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.
References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha-Synuclein, 61-140

MW: 8,460 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-synuclein (amino acids 61-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha-Synuclein, 96-140

MW: 5,217 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 96-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: rPeptide, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Alpha Synuclein-rPeptide Introduces New Proteins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sanjay Bhardwaj - rPeptide.com 
+91 41 829529 sanjayb[.]rpeptide.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any rPeptide, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From rPeptide, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsenís Somatulineģ Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentechís Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentechís Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTECô Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermeloģ (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentechís Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today ó Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)